搜索
搜索

SERVICES

研发服务

● 示例 ▶

微信截图_20210820093155
产品描述

1. Predictive biomarker discovery for the molecularly targeted therapy

Fig.1 In vivo efficacy of the molecular targeted therapy strongly correlates with the expression of predictive biomarker. (a-b) IHC staining of the predictive biomarker in patient derived xenograft tumor models. (c-d) In vivo efficacy of the molecular targeted therapy in the same set of models.

 

Fig.2 IHC staining of the predictive biomarker in patient samples.

 

 

2. Pharmacodynamic biomarker

Fig.3 PD biomarkers analysis by multiplex IHC at Yicon.

A. (a) Composite images of two targets, Ki67-blue and CD31-red together with DAPI-blue in xenograft tumor model after the treatment with vehicle. (b) low dose of the drug. (c) intermediate dose of the drug. (d) high dose of the drug. B. Data shown as the histogram.

 

 

3. Lymphocyte infiltrating analysis in tumor microenvironment after cellular therapy treatment

Fig.4 Composite images of four targets of human T cell subtypes in xenografts after treatment with vehicle (upper left) and different cellular therapies.

联系我们

地址:北京经济技术开发区隆庆街9号1号楼
邮编:100176
电话:
+86(10)6786-4680

邮箱:HR@yiconmed.com

betway必威(中国)官方网站

扫一扫,关注我们

版权所有:betway必威(中国)官方网站(北京)医药科技有限公司   备案号:京ICP备20016765号-1

网站建设:中企动力 北二分

betway必威(中国)官方网站